Repro Med Systems (KRMD) Tops Q4 EPS by 2c ; Offers Guidance

Repro Med Systems (NASDAQ: KRMD) reported Q4 EPS of ($0.02), $0.02 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $7.2 million versus the consensus estimate of $6.94 million.

GUIDANCE:

Repro Med Systems sees FY2024 revenue of $31.2-32.2 million, versus the consensus of $32.25 million.

For earnings history and earnings-related data on Repro Med Systems (KRMD) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c